These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24024585)

  • 1. Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series.
    Faez S; Lobo AM; Sobrin L; Papaliodis GN
    Clin Exp Ophthalmol; 2014; 42(4):392-5. PubMed ID: 24024585
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.
    Guignard S; Gossec L; Salliot C; Ruyssen-Witrand A; Luc M; Duclos M; Dougados M
    Ann Rheum Dis; 2006 Dec; 65(12):1631-4. PubMed ID: 16901960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis.
    Kruithof E; Kestelyn P; Elewaut C; Elewaut D; Van Den Bosch F; Mielants H; Veys EM; De Keyser F
    Ann Rheum Dis; 2002 May; 61(5):470. PubMed ID: 11959776
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term treatment with golimumab for severe uveitis.
    Miserocchi E; Modorati G; Pontikaki I; Meroni PL; Gerloni V
    Ocul Immunol Inflamm; 2014 Apr; 22(2):90-5. PubMed ID: 24143896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review.
    Calvo-Río V; de la Hera D; Blanco R; Beltrán-Catalán E; Loricera J; Cañal J; Ventosa J; Cifrián JM; Ortiz-Sanjuán F; Rueda-Gotor J; González-Vela MC; González-López M; González-Gay MA
    Clin Exp Rheumatol; 2014; 32(6):864-8. PubMed ID: 25288110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of children with uveitis treated with infliximab.
    Tugal-Tutkun I; Ayranci O; Kasapcopur O; Kir N
    J AAPOS; 2008 Dec; 12(6):611-3. PubMed ID: 18930672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behçet disease-associated uveitis successfully treated with golimumab.
    Mesquida M; Victoria Hernández M; Llorenç V; Pelegrín L; Espinosa G; Dick AD; Adán A
    Ocul Immunol Inflamm; 2013 Apr; 21(2):160-2. PubMed ID: 23252659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab in the therapy of uveitis in childhood.
    Mansour AM
    Br J Ophthalmol; 2007 Mar; 91(3):274-6. PubMed ID: 17322463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease.
    Sharma SM; Ramanan AV; Riley P; Dick AD
    Ann Rheum Dis; 2007 Jun; 66(6):840-1. PubMed ID: 17170050
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of tumor necrosis factor inhibitors in uveitis.
    Rabinovich CE
    Curr Opin Rheumatol; 2007 Sep; 19(5):482-6. PubMed ID: 17762615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis.
    Farvardin M; Afarid M; Mehryar M; Hosseini H
    Retina; 2010 Oct; 30(9):1530-5. PubMed ID: 20924267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the use of tumor necrosis factoralpha inhibitors in refractory uveitis.
    Sebastian RT; Harding SP; Bucknall RC; Pearce IA
    Arch Ophthalmol; 2006 Oct; 124(10):1505; author reply 1505-6. PubMed ID: 17030729
    [No Abstract]   [Full Text] [Related]  

  • 15. [Research update of anti-TNF-α biologic agents in the treatment of uveitis].
    Fan F; Zhou M; Luo Y
    Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):285-8. PubMed ID: 23866712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
    Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
    J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial.
    Suhler EB; Smith JR; Giles TR; Lauer AK; Wertheim MS; Kurz DE; Kurz PA; Lim L; Mackensen F; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2009 Jun; 127(6):819-22. PubMed ID: 19506209
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade.
    Paul S; Keat A
    Rheumatology (Oxford); 2005 Jan; 44(1):17-23. PubMed ID: 15328421
    [No Abstract]   [Full Text] [Related]  

  • 19. TNF inhibitors for uveitis: balancing efficacy and safety.
    Cunningham ET; Zierhut M
    Ocul Immunol Inflamm; 2010 Dec; 18(6):421-3. PubMed ID: 21091055
    [No Abstract]   [Full Text] [Related]  

  • 20. Seronegative spondyloarthropathies and the eye.
    Ali A; Samson CM
    Curr Opin Ophthalmol; 2007 Nov; 18(6):476-80. PubMed ID: 18162999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.